Insider Transactions in Q1 2024 at Arbutus Biopharma Corp (ABUS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2024
|
David C Hastings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,593
-5.01%
|
$19,186
$2.31 P/Share
|
|
Feb 02
2024
|
Karen Sims Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,358
-3.35%
|
$8,716
$2.31 P/Share
|
|
Feb 02
2024
|
Michael J. Mc Elhaugh Interim President & CEO |
SELL
Open market or private sale
|
Direct |
10,164
-0.67%
|
$20,328
$2.31 P/Share
|
|
Feb 02
2024
|
Michael J. Sofia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,982
-0.67%
|
$19,964
$2.31 P/Share
|
|
Feb 01
2024
|
David C Hastings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+37.01%
|
-
|
|
Feb 01
2024
|
Karen Sims Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+43.74%
|
-
|
|
Feb 01
2024
|
J. Christopher Naftzger General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
95,100
+50.0%
|
-
|
|
Feb 01
2024
|
Michael J. Mc Elhaugh Interim President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
123,800
+7.55%
|
-
|
|
Feb 01
2024
|
Michael J. Sofia Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,500
+6.82%
|
-
|